Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains

Immunobiology

Volumn 215, Issue 12, 2010, Pages 980-986

  Domingues Santos, Carla ^a   Loria, Roger M ^b   Rodrigues Oliveira, Luiz Gustavo ^a   Collins Kuehn, Christian ^a   Alonso Toldo, Míriam Paula ^a   Albuquerque, Sérgio ^a   do Prado Júnior, José Clóvis ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Benznidazole; Cytokines; Dehydroepiandrosterone sulfate; Nitrite Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 2; NITRITE; PRASTERONE SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HOST PARASITE INTERACTION; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; RISK REDUCTION; STRAIN DIFFERENCE; TRYPANOSOMA CRUZI;

EID: 78049312767     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.11.002     Document Type: Article

References (63)

1. Abebe F., Birkeland K.I., Gaarder P.I., Petros B., Gundersen S.G. The relationships between dehydroepiandrosterone sulphate (DHEAS), the intensity of Schistosoma mansoni infection and parasite-specific antibody responses. A cross-sectional study in residents of endemic communities in north-east Ethiopia. APMIS 2003, 111:319-328.
2. Adams L.B, Hibbs J.B, Taintor R.R., Krahenbuhl J.L. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J. Immunol. 1990, 144:2725-2729.
3. Anonymous Recommendations from a satellite meeting. Mem. Inst. Osw. Cruz 1999, 94:429-432.
4. Bice D.E., Zeledon R. Comparison of infectivity of strains of Trypanosoma cruzi (Chagas, 1909). J. Parasitol. 1970, 56:663-670.
5. Ben-Nathan D., Padgett D.A., Loria R.M. Androstenodiol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicit. J. Med. Microbiol. 1999, 48:421-431.
6. Braun M., de Titto E. Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease. Acta Physiol. Pharmacol. Latinoam. 1985, 35:1-47.
7. Brener Z. Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. São Paulo 1962, 4:389-396.
8. Cançado J.R. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. São Paulo 2002, 44:29-37.
9. Cardillo F., Voltarelli J.C., Reed S.G., Silva J.S. Regulation of Trypanosoma Cruzi infection in mice by gamma interferon and interleukin-10: the role of NK cells. Infect. Immun. 1996, 64:128-134.
10. Cardoni R.L., Antúnez M.I., Morales C., Nantes I.R. Release of reactive oxygen species by phagocytic cells in response to live parasites in mice infected with Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 1997, 56:329-334.
11. Carrero J.C., Cervantes C., Moreno-Mendoza N., Saavedra E., Morales-Montor J., Laclette J.P. Dehydroepiandrosterone decreases while cortisol increases in vitro growth and viability of Entamoeba histolytica. Microbes Infect. 2006, 8:323-331.
12. Chen C.C., Parker C.R. Adrenal androgens and the immune system. Semin. Reprod. Med. 2004, 22:369-377.
13. Cheng F. Direct agonist/antagonist functions of dehidroepiandrosterone. Endocrinology 2005, 146:4568-4576.
14. Cordeiro A.T., Thiemann O.H., Michels P.A. Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg. Med. Chem. 2009, 17:2483-2489.
15. Coronado X., Zulantay I., Rozas M., Apt W., Sánchez G., Rodríguez J., Ortiz S., Solari Dissimilar distribution of Trypanosoma cruzi clones in humans after chemotherapy with allopurinol and itraconazole 2006. J. Antimicrob. Chemother. 2006, 58:216-219.
16. Daynes R.A., DudIey D.J., Araneo B.A. Regulation of murine lymphokine production in vitro. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur. J. Immunol. 1990, 20:793-802.
17. Dias J.C., Prata A., Correia D. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev. Soc. Bras. Med. Trop. 2008, 41:193-196.
18. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 1988, 141:2407-2412.
19. Enomoto M., Adachi H., Fukami A., Furuki K., Satoh A., Otsuka M., Kumagae S.I., Nanjo Y., Shigetoh Y., Imaizumi T. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J. Am. Geriatr. Soc. 2008, 56:994-998.
20. Fallon P.G., Richardson E.J., Jones F.M., Dunne D.W. Dehydroepiandrosterone sulfate treatment of mice modulates infection with Schistosoma mansoni. Clin. Diagn. Lab. Immunol. 1998, 5:251-253.
21. Fernandes O., Souto R.P., Castro J.A., Pereira J.B., Fernandes N.C., Junqueira A.C., Naiff R.D., Barrett T.V., Degrave W., Zingales B., Campbell D.A., Coura J.R. Brazilian isolates of Trypanosoma cruzi from humans and triatomines classified into two lineages using mini-exon and ribosomal RNA sequences. Am. J. Trop. Med. Hyg. 1998, 58:807-811.
22. Filardi L.S., Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 1987, 81:755-759.
23. Funayama G.K., Prado Júnior J.C. Estudos dos caracteres de uma amostra boliviana de T. cruzi. Rev. Soc. Bras. Med. Trop. 1974, 8:75-81.
24. Gazzinelli R.T, Oswald I.P., Hieny S., James S.L., Sher A. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur. J. Immunol. 1992, 22:2501-2506.
25. Kaperska-Zajac A., Brzoza Z., Rogala B. Dehydroepiandrosterone and dehydroepiandrosterone sulphate in atopic allergy and chronic urticaria. Inflammation 2008, 31:141-145.
26. Khalifa A.M., Ibrahim I.R., el-Kerdany E.D. Coccidial infection in immunosuppressed mice: prophylaxis and treatment with dehydroepiandrosterone. East Mediterr. Health J. 2000, 6:908-918.
27. Labrie F. Adrenal androgens and intracrinology. Semin. Reprod. Med. 2004, 22:299-309.
28. Leenstra T., Kuile F.O., Kariuki S.K., Nixon C.P., Oloo A.J., Kager P.A., Kurtis J.D. Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya. J. Infect. Dis. 2003, 188:297-304.
29. Liu D., Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J. Biol. Chem. 2002, 277:21379-21388.
30. Loria R.M., Inge T.H., Cook S., Szakal A., Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J. Med. Virol. 1988, 26:301-314.
31. Loria R.M. Beta-androstenes and resistance to viral and bacterial infections. Neuroimmunomodulation 2009, 16:88-95.
32. Miles M.A., Lanhan S.M., Souza A.A., Povoa M. Further enymic characteres of Trypanosoma cruzi and their evaluation for strain identification. Trans. R. Soc. Trop. Med. Hyg. 1980, 74:221-237.
33. Minoprio P, Eisen H, Joskowicz M, Pereira P, Coutinho A. Suppression of polyclonal antibody production in murine Trypanosoma cruzi infected mice by treatment with anti-l3t4 antibodies. J. Immunol. 1987, 139:545-550.
34. Morales-Montor J., Newhouse E., Mohamed F., Baghdati A., Damian R.T. Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni. J. Infect. Dis. 2001, 183:313-320.
35. Munõz Fernández M.A., Fernández M.A., Fresno M. Synergism between tumor necrosis factor-α and interferon-g on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide dependent mechanism. Eur. J. Immunol. 1992, 22:301-307.
36. Nabors G.S., Tarleton R.L. Differential control of IFN-γ and IL-2 production during Trypanosoma cruzi infection. J. Immunol. 1991, 146:3591-3598.
37. Nathan C.F., Hibbs J.B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 1991, 3:56-70.
38. Nishikaze O. 17-KS sulfate as a biomarker in health and disease. Rinsho Byori 1998, 46:520-528.
39. Ortiz-Ortiz L., Ortega T., Capin R., Martinez T. Enhanced mononuclear phagocytic activity during Trypanosoma cruzi infection in mice. Int. Arch. Allergy Appl. Immunol. 1976, 50:232-242.
40. Ozasa H., Kita M., Inoue T., Mori T. Plasma dehydroepiandrosterone-to-cortisol ratios as an indicator of stress in gynecologic patients. Gynecol. Oncol. 1990, 37:178-182.
41. Parker L.N., Levin E.R., Lifrak E.T. Evidence for adrenocortical adaptation to severe illness. J. Clin. Endocrinol. Metab. 1985, 60:947-952.
42. Petray P.B., Rottenberg M.E., Bertot G., Corral R.S., Diaz A., Orn A., Grinstein S. Effect of anti-γ-interferon and anti-interleukin-4 administration on the resistance of mice against infection with reticulotropic and myotropic strains of Trypanosoma cruzi. Immunol. Lett. 1993, 35:77-80.
43. Petray P., Castanos-Velez E., Grinstein S., Orn A., Rottenberg M.E. Role of nitric oxide in resistance and histopathology during experimental infection with Trypanosoma cruzi. Immunol. Lett. 1995, 47:121-126.
44. Rasmussen K.R., Healey M.C., Cheng L., Yang S. Effects of dehydroepiandrosterone in immunossupressed adult mice infected with Cryptosporidium parvum. J. Parasitol. 1995, 81:429-433.
45. Reed S.G. In vivo administration of recombinant IFN-γ induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J. Immunol. 1988, 140:4342-4347.
46. Risso M.G., Garbarino G.B., Mocetti E., Campetella O., Gonzalez Cappa S.M., Buscaglia C.A., Leguizamon M.S. Differential expression of a virulence factor the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J. Infect. Dis. 2004, 189:2250-2259.
47. Saeftel M., Fleischer B., Hoerauf A. Stage-dependent role of nitric oxide in control of Trypanosoma cruzi infection. Infect. Immun. 2001, 69:2252-2259.
48. Santos C.D., Toldo M.P., do Prado Junior J.C. Trypanosoma cruzi: the effects of dehydroepiandrosterone (DHEA) treatment during experimental infection. Acta Trop. 2005, 95:109-115.
49. Santos C.D., Toldo M.P., Levy A.M., Kawasse L.M., Zucoloto S., do Prado J.C Dehydroepiandrosterone affects Trypanosoma cruzi tissue parasite burdens in rats. Acta Trop. 2007, 102:143-150.
50. Santos C.D., Toldo M.P., Santello F.H., Filipin M, del V., Brazão V., do Prado Júnior J.C. Dehydroepiandrosterone increases resistance to experimental infection by Trypanosoma cruzi. Vet. Parasitol. 2008, 153:238-243.
51. Silva L.H.P., Nussenzweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin. Biol 1953, 20:191-208.
52. Souto R.P., Fernandes O., Macedo A.M., Campbell D.A., Zingales B. Dna markers define two major phylogenetic lineages of Trypanosoma cruzi. Mol. Biochem. Parasitol. 1996, 83:141-152.
53. Spratt D.I., Longcope C., Cox P.M., Bigos S.T., Wilbur-Welling C. Differential changes in serum concentrations of androgens and estrogens (in relation with cortisol) in postmenopausal women with acute illness. J. Clin. Endocrinol. Metab. 1993, 76:1542-1547.
54. Suzuki T., Suzuki N., Daynes R.A., Engleman E.G. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin. Immunol. Immunopathol. 1991, 61:202-211.
55. Tarleton R.L. Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J. Immunol. 1990, 144:717-724.
56. Tibayrenc M., Ayala F.J. Towards a population genetics of microorganisms: the clonal theory of parasitic protozoa. Parasitol. Today 1991, 7:228-232.
57. Vespa G.N.R., Cunha F.Q., Silva J.S. Nitric oxide is involved in the control of Trypanosoma cruzi induced parasitemia and directly kills parasite in vitro. Infect. Immun. 1994, 62:5177-5182.
58. Viotti R., Vigliano C., Lococo B., Alvarez M.G., Petti M., Bertocchi G., Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti Infect. Ther. 2009, 7:157-163.
59. Torrico F., Heremans H., Rivera M.T., Van Marck E., Billiau A., Carlier Y. Endogenous IFN-γ is required for resistance to acute Trypanosoma cruzi infection in mice. J. Immunol. 1991, 146:3626-3632.
60. Vago A., Andrade L., Leite A., Reis D., Macedo A., Adad S., Tostes S., Moreira M., Filo G., Pena S. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas' disease. Am. J. Pathol. 2000, 156:1805-1809.
61. Vargas-Villavicencio JA, Larralde C, Morales-Montor J. Treatment with dehydroepiandrosterone in vivo and in vitro inhibits reproduction, growth and viability of Taenia crassiceps metacestodes. Int. J. Parasitol. 2008, 38:775-781.
62. Webb S.J., Geoghegan T.E., Prough R.A., Michael Miller K.K. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 2006, 38:89-116.
63. Widstrom R.L., Dillon J.S. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate?. Semin. Reprod. Med. 2004, 22:289-298.